Randal Wada to Humans
This is a "connection" page, showing publications Randal Wada has written about Humans.
Connection Strength
0.241
-
Wada RK. Leadership, behavioral science, and interprofessional teamwork. Transl Behav Med. 2020 10 08; 10(4):905-908.
Score: 0.035
-
Wada RK, Wong L, Flohr A, Kurahara D, Arndt R, Deutsch MJ, Ing D, Richardson K, Munro A, Kaneshige L, Mullis M, Hatae M, Albright CL. Engaging a Community Chaplaincy Resource for Interprofessional Health Care Provider Training in Facilitating Family Decision Making for Children at End-of-Life. Hawaii J Med Public Health. 2019 06; 78(6 Suppl 1):37-40.
Score: 0.032
-
Wada RK, Glaser DW, Bantum EO, Orimoto T, Steffen AD, Elia JL, Albright CL. Hawai'i's multiethnic adolescent and young adult survivors of childhood cancer: are their health behavior risks similar to state and national samples? Hawaii J Med Public Health. 2013 Nov; 72(11):380-5.
Score: 0.022
-
Kanemaru KK, Tuthill MC, Takeuchi KK, Sidell N, Wada RK. Retinoic acid induced downregulation of MYCN is not mediated through changes in Sp1/Sp3. Pediatr Blood Cancer. 2008 Apr; 50(4):806-11.
Score: 0.015
-
Iwamoto LM, Fujiwara N, Nakamura KT, Wada RK. Na-K-2Cl cotransporter inhibition impairs human lung cellular proliferation. Am J Physiol Lung Cell Mol Physiol. 2004 Sep; 287(3):L510-4.
Score: 0.011
-
Sholler GLS, Bergendahl G, Lewis EC, Kraveka J, Ferguson W, Nagulapally AB, Dykema K, Brown VI, Isakoff MS, Junewick J, Mitchell D, Rawwas J, Roberts W, Eslin D, Oesterheld J, Wada RK, Pastakia D, Harrod V, Ginn K, Saab R, Bielamowicz K, Glover J, Chang E, Hanna GK, Enriquez D, Izatt T, Halperin RF, Moore A, Byron SA, Hendricks WPD, Trent JM. Molecular-guided therapy for the treatment of patients with relapsed and refractory childhood cancers: a Beat Childhood Cancer Research Consortium trial. Genome Med. 2024 02 12; 16(1):28.
Score: 0.011
-
Wada RK, Bradford A, Moogk M, Yim R, Strong DM, Drachman J, Reems JA. Cord blood units collected at a remote site: a collaborative endeavor to collect umbilical cord blood through the Hawaii Cord Blood Bank and store the units at the Puget Sound Blood Center. Transfusion. 2004 Jan; 44(1):111-8.
Score: 0.011
-
Oesterheld J, Ferguson W, Kraveka JM, Bergendahl G, Clinch T, Lorenzi E, Berry D, Wada RK, Isakoff MS, Eslin DE, Brown VI, Roberts W, Zage P, Harrod VL, Mitchell DS, Hanson D, Saulnier Sholler GL. Eflornithine as Postimmunotherapy Maintenance in High-Risk Neuroblastoma: Externally Controlled, Propensity Score-Matched Survival Outcome Comparisons. J Clin Oncol. 2024 Jan 01; 42(1):90-102.
Score: 0.011
-
Tuthill MC, Wada RK. Targeting oncogene expression in a childhood cancer. Hawaii Med J. 2003 Oct; 62(10):224-5.
Score: 0.011
-
Eslin D, Zage PE, Bergendahl G, Lewis E, Roberts W, Kraveka J, Mitchell D, Isakoff MS, Rawwas J, Wada RK, Fluchel M, Brown VI, Ginn K, Higgins T, BeeravallyNagulapally A, Dykema K, Hanna G, Ferguson W, Saulnier Sholler GL. A phase II trial of nifurtimox combined with topotecan and cyclophosphamide for refractory or relapsed neuroblastoma and medulloblastoma. Int J Cancer. 2023 Sep 01; 153(5):1026-1034.
Score: 0.011
-
Iwamoto LM, Nakamura KT, Wada RK. Immunolocalization of a Na-K-2Cl cotransporter in human tracheobronchial smooth muscle. J Appl Physiol (1985). 2003 Apr; 94(4):1596-601.
Score: 0.010
-
Kraveka JM, Lewis EC, Bergendahl G, Ferguson W, Oesterheld J, Kim E, Nagulapally AB, Dykema KJ, Brown VI, Roberts WD, Mitchell D, Eslin D, Hanson D, Isakoff MS, Wada RK, Harrod VL, Rawwas J, Hanna G, Hendricks WPD, Byron SA, Snuderl M, Serrano J, Trent JM, Saulnier Sholler GL. A pilot study of genomic-guided induction therapy followed by immunotherapy with difluoromethylornithine maintenance for high-risk neuroblastoma. Cancer Rep (Hoboken). 2022 11; 5(11):e1616.
Score: 0.010
-
Byron SA, Hendricks WPD, Nagulapally AB, Kraveka JM, Ferguson WS, Brown VI, Eslin DE, Mitchell D, Cornelius A, Roberts W, Isakoff MS, Oesterheld JE, Wada RK, Rawwas J, Neville K, Zage PE, Harrod VL, Bergendahl G, VanSickle E, Dykema K, Bond J, Chou HC, Wei JS, Wen X, Reardon HV, Roos A, Nasser S, Izatt T, Enriquez D, Hegde AM, Cisneros F, Christofferson A, Turner B, Szelinger S, Keats JJ, Halperin RF, Khan J, Saulnier Sholler GL, Trent JM. Genomic and Transcriptomic Analysis of Relapsed and Refractory Childhood Solid Tumors Reveals a Diverse Molecular Landscape and Mechanisms of Immune Evasion. Cancer Res. 2021 12 01; 81(23):5818-5832.
Score: 0.009
-
Abe K, Dowsett L, Wada R, Hutchins K. A pediatric case of acute myeloid leukemia with KMT2A gene rearrangement t(10;11) and 16p11.2 microdeletion syndrome. Pediatr Blood Cancer. 2021 02; 68(2):e28764.
Score: 0.009
-
Lewis EC, Kraveka JM, Ferguson W, Eslin D, Brown VI, Bergendahl G, Roberts W, Wada RK, Oesterheld J, Mitchell D, Foley J, Zage P, Rawwas J, Rich M, Lorenzi E, Broglio K, Berry D, Saulnier Sholler GL. A subset analysis of a phase II trial evaluating the use of DFMO as maintenance therapy for high-risk neuroblastoma. Int J Cancer. 2020 12 01; 147(11):3152-3159.
Score: 0.009
-
Sholler GLS, Ferguson W, Bergendahl G, Bond JP, Neville K, Eslin D, Brown V, Roberts W, Wada RK, Oesterheld J, Mitchell D, Foley J, Parikh NS, Eshun F, Zage P, Rawwas J, Sencer S, Pankiewicz D, Quinn M, Rich M, Junewick J, Kraveka JM. Maintenance DFMO Increases Survival in High Risk Neuroblastoma. Sci Rep. 2018 09 27; 8(1):14445.
Score: 0.008
-
Saulnier Sholler GL, Gerner EW, Bergendahl G, MacArthur RB, VanderWerff A, Ashikaga T, Bond JP, Ferguson W, Roberts W, Wada RK, Eslin D, Kraveka JM, Kaplan J, Mitchell D, Parikh NS, Neville K, Sender L, Higgins T, Kawakita M, Hiramatsu K, Moriya SS, Bachmann AS. A Phase I Trial of DFMO Targeting Polyamine Addiction in Patients with Relapsed/Refractory Neuroblastoma. PLoS One. 2015; 10(5):e0127246.
Score: 0.006
-
Gawecka JE, Geerts D, Koster J, Caliva MJ, Sulzmaier FJ, Opoku-Ansah J, Wada RK, Bachmann AS, Ramos JW. PEA15 impairs cell migration and correlates with clinical features predicting good prognosis in neuroblastoma. Int J Cancer. 2012 Oct 01; 131(7):1556-68.
Score: 0.005
-
Kollman C, Abella E, Baitty RL, Beatty PG, Chakraborty R, Christiansen CL, Hartzman RJ, Hurley CK, Milford E, Nyman JA, Smith TJ, Switzer GE, Wada RK, Setterholm M. Assessment of optimal size and composition of the U.S. National Registry of hematopoietic stem cell donors. Transplantation. 2004 Jul 15; 78(1):89-95.
Score: 0.003
-
Tuthill MC, Wada RK, Arimoto JM, Sugino CN, Kanemaru KK, Takeuchi KK, Sidell N. N-myc oncogene expression in neuroblastoma is driven by Sp1 and Sp3. Mol Genet Metab. 2003 Sep-Oct; 80(1-2):272-80.
Score: 0.003